Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
32.00    -0.75 (-2.29%)
Bid:
31.00
Ask:
33.00
Spread: 2.00 (6.452%)
Market Cap: £57.87m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Key Technology Development Milestone

20 Nov 2023 07:00

RNS Number : 8931T
Ilika plc
20 November 2023
 

Ilika plc

("Ilika" or the "Company")

 

Achievement of Key Technology Development Milestone

 

Ilika development team reaches design-freeze milestone for first customer prototype release of Goliath battery.

 

Ilika (AIM: IKA), a pioneer in solid state battery technology, announces it has achieved its D4 development point, which is a design-freeze milestone in the Goliath roadmap upon which Ilika's first prototype for customer release, P1, is based. The P1 prototype is an intermediate milestone on Ilika's roadmap to its minimum viable product (MVP) in 2025. The P1 Goliath prototype is a solid-state pouch cell with an NMC cathode and a silicon anode.

 

The D4 development point is an important milestone for the Company, effectively marking the start of Goliath's productization journey, being the essential marker for the P1 prototype. The D4 development point means that a number of key data sets - including energy density and power density have been met while showing that the Company is firmly on track to achieve lithium-ion energy parity by the end of the current calendar. Given the data sets that are now achievable the Company will be able to create P1 samples, which comprise four layer stacks, for sale to OEMs for testing.

 

Over the next six months, Ilika will manufacture and test batches of pouch cells based on the D4 development point prior to delivering fully characterized P1 cells to up to 15 customers in 2024. Ilika is currently in discussions with its customer base for Goliath batteries, which is primarily automotive OEMs, but also includes Tier 1 automotive suppliers and consumer appliance companies.

 

Work is continuing on Ilika's roadmap through to MVP, for which the corresponding D8 development point will be achieved at the end of 2024. The MVP, or P2 prototypes will be stackable to 30 layers, underpinning licensing opportunities. Further detail re the product curve and development points can be found on page 11 of the Company's 2023 Annual Report, which is available by clicking here.

 

Graeme Purdy, Ilika CEO, stated: "Achieving our D4 development point is an important milestone on our technology roadmap, as it forms the basis of our first prototype product pilot run, with the objective of sharing prototypes with our customer base in 2024. This achievement is a clear demonstration that the Ilika team is working very efficiently with the available resources to achieve credible outcomes for our customers within the ambitious timeframes that we have set."

 

 

 

For more information contact:

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Via Walbrook PR

Jason Stewart, Chief Financial Officer

Liberum Capital Limited (Nomad and Joint Broker)

Tel: 020 3100 2000

Andrew Godber,

Nikhil Varghese

Joh. Berenberg, Gossler & Co. KG (Joint Broker)

Tel: 020 3207 8700

Matthew Armitt, Mark Whitmore, Detlir Elezi,

Natasha Ninkov

Walbrook PR Ltd

Tel: 020 7933 8780 / Ilika@walbrookpr.com

Nick Rome

Mob: 07748 325 236

 

About Ilika plc - https://www.ilika.com

Ilika specialises in the developing and commercialisation of solid state batteries. The Company's mission is to rapidly develop leading-edge IP, manufacture and license solid state batteries for markets that cannot be addressed with conventional batteries due to their safety, charge rates, energy density and life limits. The Company achieves this by using ceramic-based lithium-ion technology that is inherently safe in manufacture and usage, higher thermal tolerance and easier to recycle which differentiates our products from existing batteries.

 

The Company has two product lines. Its Stereax batteries which are designed for powering miniature medical implants, industrial wireless sensors and specialist internet of Things (IoT) applications and the Goliath large format batteries designed for EV cars and cordless appliances.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDDLFFXFLXFBB
Date   Source Headline
21st May 20267:00 amRNSIlika Trading Update and Notice of Results
10th Apr 20264:01 pmRNSCollaboration with Brompton Bicycles
18th Mar 20267:00 amRNSPositive Feedback on Safety of Goliath Cells
10th Mar 20267:00 amRNSFirst Commercial Delivery to Cirtec Medical
24th Feb 202610:21 amRNSAward of Share Options
19th Feb 20267:00 amRNS-RIlika at Yellowstone Investor Evening: Replacement
22nd Jan 20267:00 amRNSHalf-year Financial Report
21st Jan 20267:00 amRNSIlika Secures Stereax Electrode Order from Cirtec
18th Dec 20257:00 amRNSInitial Stereax M300 Shipments
11th Dec 20257:00 amRNSIlika Ships 10Ah Goliath Battery Prototypes
20th Nov 20257:00 amRNSTrading Update & Notice of Half-Year Results
21st Oct 20257:00 amRNSCommissioning Complete for Goliath Pilot Line
1st Oct 202512:00 pmRNSExercise of Options and Total Voting Rights
23rd Sep 20253:43 pmRNSResult of AGM & Award of Executive Share Options
22nd Sep 20257:00 amRNSStart of Primed Solid-State Battery Programme
28th Aug 20257:00 amRNSNotice of AGM and Posting of Annual Report
18th Aug 20257:00 amRNSStereax Battery Milestone at Cirtec Medical
17th Jul 20258:56 amRNSHolding(s) in Company
17th Jul 20257:00 amRNSFinal Results
15th Jul 20257:00 amRNSAward of Government Grant Funding
11th Jun 20252:09 pmRNSNotice of Results
4th Jun 20252:14 pmRNSHolding(s) in Company
3rd Jun 20251:57 pmRNSHolding(s) in Company
28th May 20256:00 pmRNSResult of Oversubscribed Retail Offer
22nd May 20252:16 pmRNSRetail Offer for up to £0.5 million
22nd May 20251:53 pmRNSResult of Placing & Director Subscription
21st May 20255:14 pmRNSProposed Capital Raise
7th May 202510:03 amRNS-RIlika announces 2025 Investor Day
1st May 20257:00 amRNSGoliath P1 Cells Validated by Customer Testing
15th Apr 20257:00 amRNSGoliath Battery Achieves Scale-up Milestone
6th Mar 20257:00 amRNSGoliath Development Progress
27th Feb 20257:00 amRNSAward & Exercise of Share Options
6th Feb 20253:49 pmRNSHolding(s) in Company
5th Feb 20257:00 amRNSGoliath Scale-up Progress
21st Jan 20257:00 amRNSHalf-year Results
9th Jan 20257:00 amRNSStereax Equipment Commissioning Completed
19th Dec 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
22nd Nov 20242:18 pmRNSAIM Rule 17 Schedule 2(g) Update
20th Nov 20247:00 amRNSGoliath D6 milestone reached
15th Nov 20247:00 amRNSTrading Update & Notice of Half-Year Results
10th Oct 20241:49 pmRNSHolding(s) in Company
3rd Oct 20247:00 amRNSFurther Goliath Technical Milestone Achieved
29th Aug 20247:00 amRNSPosting of Annual Report and Notice of AGM
11th Jul 20247:00 amRNSFinal Results
2nd Jul 20247:00 amRNSKey Technology Validation Milestone
1st Jul 20247:00 amRNSNominated Adviser and Joint Broker
31st May 20242:29 pmRNSHolding(s) in Company
29th May 202411:52 amRNSResults of General Meeting Open Offer and TVR
22nd May 20247:00 amRNSKey Goliath Technology Validation Milestone
16th May 20247:00 amRNSTrading Update, Notice of Results & Presentations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.